Refills Review
GLP-1 weight-loss telehealth · Independently scored 4.7/10
Best for: seeing what it charges before you answer any medical questions
Refills falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the plan
Medication
Not stated
Clinician visits
Not stated
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
No price appears before the intake. Refills (refills.com) is an online pharmacy, LegitScript-certified, running a telehealth platform that sells compounded GLP-1 prescriptions, semaglutide and tirzepatide. Daily wellness, hair growth and ED treatments round out the catalog. By its own account it operates in all 50 US states, though certain regions are documented as excluded. Shipping is free and no insurance is needed. The site itself is Webflow-hosted with dynamic content.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Refills
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Refills at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Shipping
- FDA status
- 1 FDA warning letter on record — see below
How Refills scores
Six columns, each one computed from something Refills has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
3.0/10No monthly price is published at all, so value cannot be measured against the register. Capped rather than scored.
Effectiveness25%
5.0/10Publishes no medication list or price, so what is prescribed here cannot be established. Held at the midpoint — this is a gap in the record, not a finding about the drugs.
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
3.5/101 FDA warning letter on record; does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10No published price, so what a price would include cannot be assessed. Held at the midpoint.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Refills
Last checked June 2026- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Refills involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Refills publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Refills does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering shipping.
- No comparable monthly cash price for the medication is on record — either nothing is published, or what is published is a fee, an insured copay or a per-vial rate rather than a monthly cost.
- No state list is published, so whether Refills serves your state cannot be confirmed from its site.
- 1 FDA warning letter on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
GLP-1 medications Refills offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers shipping
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
What Refills charges
Refills does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What Refills dispenses
Refills prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data.
What we could verify
Refills publishes little that can be checked from outside an intake. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- you want the price to stop moving as your dose climbs
Our read
We cannot tell you whether Refills is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. CoreAge Rx is the nearest comparison we track, and worth reading alongside this. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Refills falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Refills
Check today's price, then book the free consultation.
Where Refills is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Refills has an FDA warning letter on record, dated February 20, 2026
This letter concerns false & misleading claims/misbranded. A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Refills review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
See Refills's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.